- Home
- TGTX vs CCCS Comparison
TGTX vs CCCS Comparison
Compare TGTX & CCCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGTX
- CCCS
- Stock Information
- Founded
- TGTX 1993
- CCCS 1980
- Country
- TGTX United States
- CCCS United States
- Employees
- TGTX N/A
- CCCS N/A
- Industry
- TGTX Biotechnology: Pharmaceutical Preparations
- CCCS Computer Software: Prepackaged Software
- Sector
- TGTX Health Care
- CCCS Technology
- Exchange
- TGTX Nasdaq
- CCCS Nasdaq
- Market Cap
- TGTX 5.5B
- CCCS 5.9B
- IPO Year
- TGTX 1995
- CCCS N/A
- Fundamental
- Price
- TGTX $33.65
- CCCS $9.11
- Analyst Decision
- TGTX Strong Buy
- CCCS Buy
- Analyst Count
- TGTX 6
- CCCS 7
- Target Price
- TGTX $47.50
- CCCS $11.29
- AVG Volume (30 Days)
- TGTX 1.5M
- CCCS 5.2M
- Earning Date
- TGTX 11-04-2025
- CCCS 10-30-2025
- Dividend Yield
- TGTX N/A
- CCCS N/A
- EPS Growth
- TGTX N/A
- CCCS N/A
- EPS
- TGTX 0.36
- CCCS 0.00
- Revenue
- TGTX $454,069,000.00
- CCCS $996,961,000.00
- Revenue This Year
- TGTX $82.13
- CCCS $13.57
- Revenue Next Year
- TGTX $49.01
- CCCS $9.04
- P/E Ratio
- TGTX $92.64
- CCCS $30,350.00
- Revenue Growth
- TGTX 30.96
- CCCS 9.60
- 52 Week Low
- TGTX $22.61
- CCCS $8.14
- 52 Week High
- TGTX $46.48
- CCCS $12.88
- Technical
- Relative Strength Index (RSI)
- TGTX 48.14
- CCCS 46.52
- Support Level
- TGTX $34.01
- CCCS $8.70
- Resistance Level
- TGTX $35.52
- CCCS $9.15
- Average True Range (ATR)
- TGTX 1.28
- CCCS 0.27
- MACD
- TGTX -0.24
- CCCS -0.00
- Stochastic Oscillator
- TGTX 16.02
- CCCS 48.52
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
About CCCS CCC Intelligent Solutions Holdings Inc.
CCC Intelligent Solutions Holdings Inc is a provider of cloud, mobile, AI, telematics, hyperscale technologies and applications for the property and casualty insurance economy. The company's SaaS platform connects trading partners, facilitates commerce, and supports mission-critical, and AI-enabled digital workflows. It operates in a single segment being Domestic segment which provides SAAS platform for the P&C insurance economy and derives revenues from providing customers with software subscriptions to the platform in addition to providing professional services and non-software services. The company has its presence in United States and China. Majority of the revenue is generated from United States.